

§Appl. No. 10/049,464  
Amdt. dated September 22, 2005  
Reply to Office Action of, March 22, 2005

**In the Specification:**

Please amend the specification as follows:

**On page 2 after the first full paragraph please insert the following header and subsequent paragraphs:**

**BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 shows reaction of cells with Anti-CD28-PE antibody.

Fig.2 (A-C) that monoclonal antibody CMY-2 differentiates transfected and un-transfected cells using antibodies against human CD28.

Fig. 3 shows the proliferative response to unseparated lymph node cells of the rat to the antibodies JJ319 and JJ316.

Fig. 4 shows CD28-specific monoclonal antibodies lead to an increase of the CD4 T-cell count in the intact organism.

Fig 5 (A-B) shows the activation of the proliferation of CD4 T cells.

Fig. 6 (A-B) shows T cell proliferation in response to aCD28.

Fig. 7 shows the proliferation of unseparated PBMC of not infected donors measured by the integration of <sup>3</sup>H-thymidine.

§Appl. No. 10/049,464  
Amdt. dated September 22, 2005  
Reply to Office Action of, March 22, 2005

Fig. 8 (A-B) shows the activating effect of aCD28 on the proliferation of PBMC from HIIV-infected humans and monkeys, respectively.

Fig. 9 shows proliferation of PBMC in response to HAART.

Fig. 10 shows aCD28-induced proliferation was improved by HAART.

Fig 11 shows the aCD28 stimulation indices massive virus production.

Fig. 12 shows HIV production after treatment with aCD28 and HAART.

Fig. 13 shows the pro-viral HIV DNA is not detectable after combined treatment with HAART and aCD28.